Similarly, serum levels of carcinoembryonic antigen (CEA), CA 19-9, and prostate specific antigen (PSA) can be used as surrogate markers of tumor burden changes in colon, pancreas, and prostate carcinomas. The gene discussed is CEACAM5; the disease is neoplasm.